Abstracts tagged "Scleroderma, Systemic"

Abstract Number: 0128 • ACR Convergence 2023
Incidence, Trends, and Determinants of Multimorbidity in Systemic Sclerosis: Data from a Population-based Cohort
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: To evaluate the burden, longitudinal trends, and drivers of multimorbidity (MM; the presence of ≥2 morbidities) in patients with Systemic Sclerosis (SSc) vs. age-…
Abstract Number: 0935 • ACR Convergence 2023
Sodium Pyruvate Improves Mitochondrial Fitness in SSc Fibroblasts to Prevent Fibroblast-to-myofibroblast Transition and Fibrotic Remodeling
Xiang Zhou¹, Thuong Trinh-Minh¹, Alexandru-Emil Matei¹, Honglin Zhu², Hermina Györfi¹, Cuong Tran Manh¹, Xuezhi Hong¹ and Joerg Distler¹, ¹Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ²3 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany. 5 Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: Systematic sclerosis (SSc) is an autoimmune disease characteristic by fibroblast transition and overproduction of extracellular matrix, yet with limited treatment. Recent studies provided evidence…
Abstract Number: 2354 • ACR Convergence 2023
Is Midkine a Novel Biomarker for Acro-osteolysis in Systemic Sclerosis?
Ganiat Adeogun¹, Venkateswara Gogulamudi², Meridith Balbach¹, Anthony Donato² and Tracy Frech¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Acro-osteolysis is a hand complication in systemic sclerosis (SSc) characterized by the destruction of distal digital bone possibly related to repetitive ischemia-reperfusion injury. Diagnosis…
Abstract Number: 0129 • ACR Convergence 2023
Rising Incidence and High Mortality of Systemic Sclerosis: A Population-based Cohort Study (2010-2020)
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: Systemic Sclerosis (SSc) is a rare chronic inflammatory disease characterized by immune-mediated dysfunction, vasculopathy and widespread internal organ fibrosis; and the highest case fatality…
Abstract Number: 0948 • ACR Convergence 2023
Nintedanib Alters Fibroblast and Macrophage Diversity in a 3D Skin Model of Systemic Sclerosis (SSc)
Noelle Kosarek¹, Tamar Abel², Sasha Shenk³, Tammara Wood², Jonathan Garlick⁴, Patricia Pioli⁵ and Michael Whitfield⁵, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth College, Hanover, NH, ³Tufts University, Boston, MA, ⁴Tufts University School of Dental Medicine, Boston, MA, ⁵Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs. While the tyrosine kinase inhibitor Nintedanib is…
Abstract Number: 2356 • ACR Convergence 2023
A Macrophage-Specific Mechanism for Mycophenolate Mofetil in the Treatment of Systemic Sclerosis
Emily Morris, Rezvan Parvizi, Patricia Pioli and Michael Whitfield, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by inflammation and fibrosis. Treatment with mycophenolate mofetil (MMF), an inhibitor of lymphocyte…
Abstract Number: 0256 • ACR Convergence 2023
Nintedanib in Combination with Immunosuppressive Agents Improves Forced Vital Capacity in Connective Tissue Disease-associated PF-ILD: A Single-center Study
Yusuke Ushio¹, Risa Wakiya², Tomohiro Kameda², Shusaku Nakashima², Hiromi Shimada², Taichi Miyagi³, Koichi Sugihara⁴, Rina Mino⁵, Mao Mizusaki², Kanako Chujo⁶, Ryoko Kagawa⁷, Hayamasa Yamaguchi⁷ and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁴Kagawa University, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁶Kagawa University, Miki, Kita District, Kagawa, Japan, ⁷Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Japanese patients with connective tissue disease (CTD) are more likely to have interstitial lung disease (CTD-ILD) than those in Western countries and many CTD-ILDs…
Abstract Number: 0958 • ACR Convergence 2023
Shared Genetic Susceptibility Between Systemic Sclerosis and Primary Biliary Cholangitis: Analyses from Genome-Wide Association Studies
Yiming Luo¹, Atlas Khan², Gabriel Perreault³, Lili Liu², Cue Hyunkyu Lee⁴, Pravitt Gourh⁵, Sydney Pomenti³, Krzysztof Kiryluk² and Elana Bernstein⁶, ¹Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ²Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ³Division of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ⁴Department of Biostatistics, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY
Background/Purpose: Systemic sclerosis (SSc) is a multi-system autoimmune disorder characterized by organ inflammation, fibrosis, and vasculopathy. Primary biliary cholangitis (PBC) is an autoimmune disorder involving…
Abstract Number: 2366 • ACR Convergence 2023
Spatial Frequency Domain Imaging as a Novel Method to Quantify Longitudinal Skin Changes in Scleroderma
Hung Vo¹, Aarohi Mehendale², Anahita Pilvar³, Eugene Kissin⁴, Marcin Trojanowski⁵, Michael York⁶, Darren Roblyer² and Andreea Bujor⁶, ¹Boston Medical Center, Peabody, MA, ²Department of Biomedical Engineering, Boston University, Boston, MA, ³Department of Electrical and Computer Engineering, Boston University, Boston, MA, ⁴Boston University, Newton, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶Boston University, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by excessive collagen deposition in the skin and internal organs, along with vascular dysfunction. The modified…
Abstract Number: 0332 • ACR Convergence 2023
Initial Characterization of a Skin Symptom Questionnaire for Patients with Systemic Sclerosis
Jeong Min Yu¹, John VanBuren², Angela Child², Jessica Alvey², Lisa Mandl³, Laura Pinheiro⁴, Shervin Assassi⁵, Elana Bernstein⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Faye Hant¹¹, Laura Hummers¹², Dinesh Khanna¹³, Kimberly Lakin¹, Dorota Lebiedz-Odrobina¹⁴, Yiming Luo¹⁵, Ashima Makol¹⁶, Jerry Molitor¹⁷, Duncan Moore¹⁸, Carrie Richardson¹⁹, Nora Sandorfi²⁰, Ami Shah²¹, Ankoor Shah²², Victoria Shanmugam²³, Brian Skaug²⁴, Virginia Steen²⁵, Elizabeth Volkmann²⁶ and Jessica Gordon¹, ¹Hospital for Special Surgery, New York, NY, ²University of Utah, Salt Lake City, UT, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Weill Cornell Medicine College, New York, NY, ⁵University of Texas McGovern Medical School at Houston, Houston, TX, ⁶Columbia University, New York, NY, ⁷Massachusetts General Hospital, Boston, MA, ⁸Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁹Scleroderma Research Foundation, Brisbane, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins University, Baltimore, MD, ¹³University of Michigan, Ann Arbor, MI, ¹⁴University of Utah, Cottonwood Heights, UT, ¹⁵Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ¹⁶Mayo Clinic, Rochester, MN, Rochester, MN, ¹⁷University of Minnesota, Minneapolis, MN, ¹⁸Northwestern Memorial Hospital, Chicago, IL, ¹⁹Northwestern University, Riverside, IL, ²⁰University of Pennsylvania, Philadelphia, PA, ²¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ²²Duke University, Durham, NC, ²³Victoria Shanmugam, MD, Great Falls, VA, ²⁴Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²⁵Georgetown University School of Medicine, Washington, DC, ²⁶University of California Los Angeles, Los Angeles, CA
Background/Purpose: Skin disease is a hallmark of systemic sclerosis (SSc). The modified Rodnan skin score (mRSS) is physician performed measurement that assesses the extent and…
Abstract Number: 1142 • ACR Convergence 2023
A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease
Nikita Jhawar, Claire Wilson, Andy Abril, Li Zhuo and Yaohua Ma, Mayo Clinic, Jacksonville, FL
Background/Purpose: Connective tissue diseases such as scleroderma are frequently associated with interstitial lung disease (ILD). Detection of autoantibodies is crucial in characterizing disease phenotypes, but…
Abstract Number: 2595 • ACR Convergence 2023
A Randomized Controlled Trial to Compare the Efficacy and Safety of Tacrolimus with Mycophenolate Mofetil in Patients with Systemic Sclerosis – Interstitial Lung Disease ( INSIST TRIAL)
Shefali Khanna Sharma¹, Jithin Mathew¹, Chirag Kopp¹, Varun Dhir², Sahajal Dhooria³, Anindita Sinha¹ and Sanjay Jain¹, ¹Post Graduate Institute of Medical Education and Research, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³PGI CHANDIGARH, Chandigarh, India
Background/Purpose: Interstitial lung disease in systemic sclerosis(SSc-ILD) is heterogeneous with limited therapeutic options. Mycophenolate mofetil (MMF) is the most commonly used first line agent for…
Abstract Number: 0611 • ACR Convergence 2023
Demographics and Clinical Features Associated with Small Bowel Hypomotility in Systemic Sclerosis
Jenice Cheah¹, Jamie Perin², Michael Hughes³, Julie Paik⁴, Christopher Mecoli², Laura Hummers⁴, Ami Shah⁵, Fred Wigley⁶ and Zsuzsanna McMahan⁷, ¹University of California Los Angeles, Los Angeles, CA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ⁴Johns Hopkins University, Baltimore, MD, ⁵Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ⁶Department of Rheumatology, Johns Hopkins Medicine, Baltimore, MD, ⁷Johns Hopkins Rheumatology, Lutherville, MD
Background/Purpose: The gastrointestinal (GI) tract is the second most commonly affected organ in patients with systemic sclerosis (SSc). It is estimated that the small bowel…
Abstract Number: 1516 • ACR Convergence 2023
Systemic Sclerosis Gastrointestinal Tract Vascular Biomarkers of Symptomatic Disease Activity
Venkateswara Gogulamudi¹, Sarah Wood², Elizabeth Johnson², Aaron Petrey³, Anthony Donato⁴ and Tracy Frech², ¹Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT, ²Vanderbilt University Medical Center, Nashville, TN, ³University of Utah, Salt Lake City, UT, ⁴University of Utah and Salt Lake VAMC, Salt Lake City, UT
Background/Purpose: Gastrointestinal tract symptoms are common in systemic sclerosis (SSc). The Scleroderma Clinical Trials Consortium University of California Los Angeles Gastrointestinal Tract Questionnaire (GIT 2.0)…
Abstract Number: 0612 • ACR Convergence 2023
COVID Vaccinations and Infections Among Individuals with Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study
Kimberly Lakin¹, Jessica Gordon¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier², Richard Henry², Christopher Denton⁴, Luc Mouthon⁵, Robert Spiera⁶ and Brett Thombs², ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, ³Radboud University, Nijmegen, Netherlands, ⁴University College London, London, United Kingdom, ⁵Hopital Cochin - Paris University, Paris, France, ⁶Hosptial for Special Surgery, New York, NY
Background/Purpose: We previously surveyed individuals with systemic sclerosis (SSc) enrolled in Scleroderma Patient-centered Intervention Network (SPIN) Cohort between April-May 2021 to determine COVID-19 vaccination rates,…

« Previous Page
1
…
3
4
5
6
7
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].